Home › Trial NCT00226668
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
- Trial IDNCT00226668
- StatusWithdrawn
- PhasePhase 3
- Study typeInterventional
- SponsorCeltic Pharma Development Services
- Enrollment120
- Start date2006-01
- ConditionsBrain Edema · Brain Tumor
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.